Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Medicenna Therapeutics Corp (MDNA)

Medicenna Therapeutics Corp (MDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Could CRISPR Therapeutics Help You Become a Millionaire? Motley Fool - Tue Dec 27, 2022

The gene-editing stock still has plenty of promise.

VRTX : 483.00 (-3.15%)
MDNA : 0.1570 (-13.16%)
CRSP : 48.92 (+1.30%)
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline Globe Newswire - Thu Aug 11, 2022

TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Announces Pricing of US$20 Million Public Offering of Units Globe Newswire - Tue Aug 9, 2022

TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units Globe Newswire - Mon Aug 8, 2022

TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022 Globe Newswire - Fri Aug 5, 2022

TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study Globe Newswire - Wed Jul 27, 2022

-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights Globe Newswire - Wed Jun 22, 2022

--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent Globe Newswire - Thu Jun 9, 2022

Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered SuperkinesDelivery of selected Bcl-2...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022 Globe Newswire - Tue Jun 7, 2022

TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting Globe Newswire - Wed May 11, 2022

-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) ...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.28 (-3.39%)

Barchart Exclusives

Is AMD Stock a Buy for Data Center Upside? Barchart - 1 hour ago
AMD failed to grab the spotlight at its AI event. However, is there more under the hood? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot